메뉴 건너뛰기




Volumn 4, Issue 1, 2016, Pages

Current clinical trials testing the combination of immunotherapy with radiotherapy

Author keywords

Abscopal effect; Antitumor immunity; CTLA 4; Immunotherapy; PD 1; PD L1; Radiotherapy; Stereotactic body radiation therapy; TGF

Indexed keywords

ALPHA INTERFERON; ATEZOLIZUMAB; CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; FRESOLIMUMAB; GALUNISERTIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; OX40 LIGAND; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; SIPULEUCEL T; TICILIMUMAB;

EID: 84997810104     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0156-7     Document Type: Article
Times cited : (322)

References (92)
  • 1
    • 67649359533 scopus 로고    scopus 로고
    • Systemic effects of local radiotherapy
    • Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718-26.
    • (2009) Lancet Oncol , vol.10 , Issue.7 , pp. 718-726
    • Formenti, S.C.1    Demaria, S.2
  • 2
    • 0020321584 scopus 로고
    • Radiation sensitivity of human erythropoietic and granulopoietic progenitor cells in the blood and in the bone marrow
    • Grilli G, Nothdurft W, Fliedner TM. Radiation sensitivity of human erythropoietic and granulopoietic progenitor cells in the blood and in the bone marrow. Int J Radiat Biol Relat Stud Phys Chem Med. 1982;41(6):685-7.
    • (1982) Int J Radiat Biol Relat Stud Phys Chem Med , vol.41 , Issue.6 , pp. 685-687
    • Grilli, G.1    Nothdurft, W.2    Fliedner, T.M.3
  • 3
    • 0020608547 scopus 로고
    • Late effects on human bone marrow after extended field radiotherapy
    • Parmentier C, Morardet N, Tubiana M. Late effects on human bone marrow after extended field radiotherapy. Int J Radiat Oncol Biol Phys. 1983;9(9):1303-11.
    • (1983) Int J Radiat Oncol Biol Phys , vol.9 , Issue.9 , pp. 1303-1311
    • Parmentier, C.1    Morardet, N.2    Tubiana, M.3
  • 4
    • 0019975724 scopus 로고
    • Total body irradiation (TBI) before bone marrow transplantation in leukaemia: a co-operative study from the European Group for Bone Marrow Transplantation
    • Barrett A. Total body irradiation (TBI) before bone marrow transplantation in leukaemia: a co-operative study from the European Group for Bone Marrow Transplantation. Br J Radiol. 1982;55(656):562-7.
    • (1982) Br J Radiol , vol.55 , Issue.656 , pp. 562-567
    • Barrett, A.1
  • 5
    • 0022831791 scopus 로고
    • Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation
    • Deeg HJ, Sullivan KM, Buckner CD, Storb R, Appelbaum FR, Clift RA, Doney K, Sanders JE, Witherspoon RP, Thomas ED. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant. 1986;1(2):151-7.
    • (1986) Bone Marrow Transplant , vol.1 , Issue.2 , pp. 151-157
    • Deeg, H.J.1    Sullivan, K.M.2    Buckner, C.D.3    Storb, R.4    Appelbaum, F.R.5    Clift, R.A.6    Doney, K.7    Sanders, J.E.8    Witherspoon, R.P.9    Thomas, E.D.10
  • 7
    • 84880093055 scopus 로고    scopus 로고
    • Radiation as an immunological adjuvant: current evidence on dose and fractionation
    • Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.
    • (2012) Front Oncol , vol.2 , pp. 153
    • Demaria, S.1    Formenti, S.C.2
  • 8
    • 84902480054 scopus 로고    scopus 로고
    • Is tumor (R)ejection by the immune system the "5th R" of radiobiology?
    • Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology. 2014;3(1):e28133.
    • (2014) Oncoimmunology , vol.3 , Issue.1
    • Golden, E.B.1    Formenti, S.C.2
  • 9
    • 84875039618 scopus 로고    scopus 로고
    • Combining radiotherapy and cancer immunotherapy: a paradigm shift
    • Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256-65.
    • (2013) J Natl Cancer Inst , vol.105 , Issue.4 , pp. 256-265
    • Formenti, S.C.1    Demaria, S.2
  • 10
    • 84955417454 scopus 로고    scopus 로고
    • In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
    • Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015;33(51):7415-22.
    • (2015) Vaccine , vol.33 , Issue.51 , pp. 7415-7422
    • Vanpouille-Box, C.1    Pilones, K.A.2    Wennerberg, E.3    Formenti, S.C.4    Demaria, S.5
  • 11
    • 84953874197 scopus 로고    scopus 로고
    • Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
    • Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509.
    • (2015) Lancet Oncol , vol.16 , Issue.13 , pp. e498-e509
    • Sharabi, A.B.1    Lim, M.2    DeWeese, T.L.3    Drake, C.G.4
  • 15
    • 69949085196 scopus 로고    scopus 로고
    • Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody
    • Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379-88.
    • (2009) Clin Cancer Res , vol.15 , Issue.17 , pp. 5379-5388
    • Dewan, M.Z.1    Galloway, A.E.2    Kawashima, N.3    Dewyngaert, J.K.4    Babb, J.S.5    Formenti, S.C.6    Demaria, S.7
  • 16
    • 20444406500 scopus 로고    scopus 로고
    • Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
    • Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516-23.
    • (2005) J Immunol , vol.174 , Issue.12 , pp. 7516-7523
    • Lugade, A.A.1    Moran, J.P.2    Gerber, S.A.3    Rose, R.C.4    Frelinger, J.G.5    Lord, E.M.6
  • 17
    • 84880706152 scopus 로고    scopus 로고
    • Oncology meets immunology: the cancer-immunity cycle
    • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
    • (2013) Immunity , vol.39 , Issue.1 , pp. 1-10
    • Chen, D.S.1    Mellman, I.2
  • 18
    • 35548936833 scopus 로고    scopus 로고
    • Models, mechanisms and clinical evidence for cancer dormancy
    • Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-46.
    • (2007) Nat Rev Cancer , vol.7 , Issue.11 , pp. 834-846
    • Aguirre-Ghiso, J.A.1
  • 19
    • 84857793524 scopus 로고    scopus 로고
    • Decisions about dendritic cells: past, present, and future
    • Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22.
    • (2012) Annu Rev Immunol , vol.30 , pp. 1-22
    • Steinman, R.M.1
  • 21
    • 84877356104 scopus 로고    scopus 로고
    • Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line
    • Parker JJ, Jones JC, Strober S, Knox SJ. Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol. 2013;148(1):44-55.
    • (2013) Clin Immunol , vol.148 , Issue.1 , pp. 44-55
    • Parker, J.J.1    Jones, J.C.2    Strober, S.3    Knox, S.J.4
  • 22
    • 45149111788 scopus 로고    scopus 로고
    • Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
    • Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008;224:141-65.
    • (2008) Immunol Rev , vol.224 , pp. 141-165
    • Peggs, K.S.1    Quezada, S.A.2    Allison, J.P.3
  • 24
    • 79953241540 scopus 로고    scopus 로고
    • Melanoma drug wins US approval
    • Ledford H. Melanoma drug wins US approval. Nature. 2011;471(7340):561.
    • (2011) Nature , vol.471 , Issue.7340 , pp. 561
    • Ledford, H.1
  • 25
    • 12244252335 scopus 로고    scopus 로고
    • Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
    • Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728-34.
    • (2005) Clin Cancer Res , vol.11 , Issue.2 , pp. 728-734
    • Demaria, S.1    Kawashima, N.2    Yang, A.M.3    Devitt, M.L.4    Babb, J.S.5    Allison, J.P.6    Formenti, S.C.7
  • 30
    • 85003053854 scopus 로고    scopus 로고
    • An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer
    • Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365-72.
    • (2013) Cancer Immunol Res , vol.1 , Issue.6 , pp. 365-372
    • Golden, E.B.1    Demaria, S.2    Schiff, P.B.3    Chachoua, A.4    Formenti, S.C.5
  • 32
    • 84964229943 scopus 로고    scopus 로고
    • Abscopal responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and ipilimumab: evidence for the in situ vaccination hypothesis of radiation
    • Golden EB, Chachoua A, Fenton-Kerimian M, Demaria S, Formenti S. Abscopal responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and ipilimumab: evidence for the in situ vaccination hypothesis of radiation. Int J Radiat Oncol Biol Phys. 2015;93:S66-67.
    • (2015) Int J Radiat Oncol Biol Phys , vol.93 , pp. S66-67
    • Golden, E.B.1    Chachoua, A.2    Fenton-Kerimian, M.3    Demaria, S.4    Formenti, S.5
  • 34
    • 84880508629 scopus 로고    scopus 로고
    • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    • Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813-21.
    • (2013) Ann Oncol , vol.24 , Issue.7 , pp. 1813-1821
    • Slovin, S.F.1    Higano, C.S.2    Hamid, O.3    Tejwani, S.4    Harzstark, A.5    Alumkal, J.J.6    Scher, H.I.7    Chin, K.8    Gagnier, P.9    McHenry, M.B.10
  • 35
    • 84901641673 scopus 로고    scopus 로고
    • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
    • Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12.
    • (2014) Lancet Oncol , vol.15 , Issue.7 , pp. 700-712
    • Kwon, E.D.1    Drake, C.G.2    Scher, H.I.3    Fizazi, K.4    Bossi, A.5    Eertwegh, A.J.6    Krainer, M.7    Houede, N.8    Santos, R.9    Mahammedi, H.10
  • 36
    • 84929411847 scopus 로고    scopus 로고
    • Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
    • Gangadhar TC, Salama AK. Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. Onco Targets Ther. 2015;8:929-37.
    • (2015) Onco Targets Ther , vol.8 , pp. 929-937
    • Gangadhar, T.C.1    Salama, A.K.2
  • 39
    • 67549086678 scopus 로고    scopus 로고
    • Transforming growth factor-beta in breast cancer: too much, too late
    • Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009;11(1):202.
    • (2009) Breast Cancer Res , vol.11 , Issue.1 , pp. 202
    • Barcellos-Hoff, M.H.1    Akhurst, R.J.2
  • 40
    • 0028177037 scopus 로고
    • Transforming growth factor-beta activation in irradiated murine mammary gland
    • Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93(2):892-9.
    • (1994) J Clin Invest , vol.93 , Issue.2 , pp. 892-899
    • Barcellos-Hoff, M.H.1    Derynck, R.2    Tsang, M.L.3    Weatherbee, J.A.4
  • 43
    • 84937525789 scopus 로고    scopus 로고
    • Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
    • Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795-803.
    • (2015) Lancet Oncol , vol.16 , Issue.7 , pp. 795-803
    • Golden, E.B.1    Chhabra, A.2    Chachoua, A.3    Adams, S.4    Donach, M.5    Fenton-Kerimian, M.6    Friedman, K.7    Ponzo, F.8    Babb, J.S.9    Goldberg, J.10
  • 44
    • 22144497779 scopus 로고    scopus 로고
    • Vaccines in cancer: GVAX, a GM-CSF gene vaccine
    • Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines. 2005;4(3):259-74.
    • (2005) Expert Rev Vaccines , vol.4 , Issue.3 , pp. 259-274
    • Nemunaitis, J.1
  • 46
    • 0032784492 scopus 로고    scopus 로고
    • Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
    • Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17(8):2521-9.
    • (1999) J Clin Oncol , vol.17 , Issue.8 , pp. 2521-2529
    • Figlin, R.A.1    Thompson, J.A.2    Bukowski, R.M.3    Vogelzang, N.J.4    Novick, A.C.5    Lange, P.6    Steinberg, G.D.7    Belldegrun, A.S.8
  • 51
    • 0032471712 scopus 로고    scopus 로고
    • Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
    • Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg. 1998;228(3):307-19.
    • (1998) Ann Surg , vol.228 , Issue.3 , pp. 307-319
    • Rosenberg, S.A.1    Yang, J.C.2    White, D.E.3    Steinberg, S.M.4
  • 52
    • 78049264752 scopus 로고    scopus 로고
    • The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
    • Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010;46(16):2926-35.
    • (2010) Eur J Cancer , vol.46 , Issue.16 , pp. 2926-2935
    • Johannsen, M.1    Spitaleri, G.2    Curigliano, G.3    Roigas, J.4    Weikert, S.5    Kempkensteffen, C.6    Roemer, A.7    Kloeters, C.8    Rogalla, P.9    Pecher, G.10
  • 56
    • 79251579661 scopus 로고    scopus 로고
    • Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
    • Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011;22(2):348-54.
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 348-354
    • Picozzi, V.J.1    Abrams, R.A.2    Decker, P.A.3    Traverso, W.4    O'Reilly, E.M.5    Greeno, E.6    Martin, R.C.7    Wilfong, L.S.8    Rothenberg, M.L.9    Posner, M.C.10
  • 57
    • 84951815939 scopus 로고    scopus 로고
    • Phase 2 randomized controlled trial of radiation therapy plus concurrent interferon-alpha and retinoic acid versus cisplatin for stage III cervical carcinoma
    • Basu P, Jenson AB, Majhi T, Choudhury P, Mandal R, Banerjee D, Biswas J, Pan J, Rai SN, Ghim SJ, et al. Phase 2 randomized controlled trial of radiation therapy plus concurrent interferon-alpha and retinoic acid versus cisplatin for stage III cervical carcinoma. Int J Radiat Oncol Biol Phys. 2016;94(1):102-10.
    • (2016) Int J Radiat Oncol Biol Phys , vol.94 , Issue.1 , pp. 102-110
    • Basu, P.1    Jenson, A.B.2    Majhi, T.3    Choudhury, P.4    Mandal, R.5    Banerjee, D.6    Biswas, J.7    Pan, J.8    Rai, S.N.9    Ghim, S.J.10
  • 59
    • 1442332187 scopus 로고    scopus 로고
    • TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors
    • Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22(4):592-601.
    • (2004) J Clin Oncol , vol.22 , Issue.4 , pp. 592-601
    • Senzer, N.1    Mani, S.2    Rosemurgy, A.3    Nemunaitis, J.4    Cunningham, C.5    Guha, C.6    Bayol, N.7    Gillen, M.8    Chu, K.9    Rasmussen, C.10
  • 61
    • 79953062841 scopus 로고    scopus 로고
    • A pilot feasibility study of TNFerade biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer
    • Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, et al. A pilot feasibility study of TNFerade biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology. 2010;79(5-6):382-8.
    • (2010) Oncology , vol.79 , Issue.5-6 , pp. 382-388
    • Citrin, D.1    Camphausen, K.2    Wood, B.J.3    Quezado, M.4    Denobile, J.5    Pingpank, J.F.6    Royal, R.E.7    Alexander, H.R.8    Seidel, G.9    Steinberg, S.M.10
  • 62
    • 84855826028 scopus 로고    scopus 로고
    • EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
    • Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012;75(2):332-8.
    • (2012) Gastrointest Endosc , vol.75 , Issue.2 , pp. 332-338
    • Hecht, J.R.1    Farrell, J.J.2    Senzer, N.3    Nemunaitis, J.4    Rosemurgy, A.5    Chung, T.6    Hanna, N.7    Chang, K.J.8    Javle, M.9    Posner, M.10
  • 63
    • 84861530230 scopus 로고    scopus 로고
    • Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer
    • Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, Chak A, Soetikno R. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc. 2012;75(6):1139-1146 e1132.
    • (2012) Gastrointest Endosc , vol.75 , Issue.6 , pp. 1139-1146 e1132
    • Chang, K.J.1    Reid, T.2    Senzer, N.3    Swisher, S.4    Pinto, H.5    Hanna, N.6    Chak, A.7    Soetikno, R.8
  • 64
    • 84874578991 scopus 로고    scopus 로고
    • A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation
    • Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013;24(3):769-76.
    • (2013) Ann Oncol , vol.24 , Issue.3 , pp. 769-776
    • Seiwert, T.Y.1    Darga, T.2    Haraf, D.3    Blair, E.A.4    Stenson, K.5    Cohen, E.E.6    Salama, J.K.7    Villaflor, V.8    Witt, M.E.9    Lingen, M.W.10
  • 65
    • 84875729716 scopus 로고    scopus 로고
    • Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results
    • Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013;31(7):886-94.
    • (2013) J Clin Oncol , vol.31 , Issue.7 , pp. 886-894
    • Herman, J.M.1    Wild, A.T.2    Wang, H.3    Tran, P.T.4    Chang, K.J.5    Taylor, G.E.6    Donehower, R.C.7    Pawlik, T.M.8    Ziegler, M.A.9    Cai, H.10
  • 66
    • 84877059530 scopus 로고    scopus 로고
    • The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
    • Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25(2):230-7.
    • (2013) Curr Opin Immunol , vol.25 , Issue.2 , pp. 230-237
    • Moran, A.E.1    Kovacsovics-Bankowski, M.2    Weinberg, A.D.3
  • 68
    • 38949156782 scopus 로고    scopus 로고
    • Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer
    • Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, Hommura F, Nishimura T, Nishimura M. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci. 2008;99(2):361-7.
    • (2008) Cancer Sci , vol.99 , Issue.2 , pp. 361-367
    • Yokouchi, H.1    Yamazaki, K.2    Chamoto, K.3    Kikuchi, E.4    Shinagawa, N.5    Oizumi, S.6    Hommura, F.7    Nishimura, T.8    Nishimura, M.9
  • 72
    • 14744275172 scopus 로고    scopus 로고
    • Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma
    • Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28(2):129-35.
    • (2005) J Immunother , vol.28 , Issue.2 , pp. 129-135
    • Chi, K.H.1    Liu, S.J.2    Li, C.P.3    Kuo, H.P.4    Wang, Y.S.5    Chao, Y.6    Hsieh, S.L.7
  • 74
    • 0032695108 scopus 로고    scopus 로고
    • Natural adjuvants: endogenous activators of dendritic cells
    • Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5(11):1249-55.
    • (1999) Nat Med , vol.5 , Issue.11 , pp. 1249-1255
    • Gallucci, S.1    Lolkema, M.2    Matzinger, P.3
  • 75
    • 11344265206 scopus 로고    scopus 로고
    • Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy
    • Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005;11(1):361-9.
    • (2005) Clin Cancer Res , vol.11 , Issue.1 , pp. 361-369
    • Mason, K.A.1    Ariga, H.2    Neal, R.3    Valdecanas, D.4    Hunter, N.5    Krieg, A.M.6    Whisnant, J.K.7    Milas, L.8
  • 76
    • 84871230007 scopus 로고    scopus 로고
    • Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer
    • Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, Adams S, Demaria S. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 2012;18(24):6668-78.
    • (2012) Clin Cancer Res , vol.18 , Issue.24 , pp. 6668-6678
    • Dewan, M.Z.1    Vanpouille-Box, C.2    Kawashima, N.3    DiNapoli, S.4    Babb, J.S.5    Formenti, S.C.6    Adams, S.7    Demaria, S.8
  • 77
    • 84872328340 scopus 로고    scopus 로고
    • Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
    • Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121(2):251-9.
    • (2013) Blood , vol.121 , Issue.2 , pp. 251-259
    • Dovedi, S.J.1    Melis, M.H.2    Wilkinson, R.W.3    Adlard, A.L.4    Stratford, I.J.5    Honeychurch, J.6    Illidge, T.M.7
  • 78
    • 84915819392 scopus 로고    scopus 로고
    • Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study
    • Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, Nagai Y, Mitsuhashi N, Ochiai K, Noda K. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol. 2014;25(5):1011-7.
    • (2014) Ann Oncol , vol.25 , Issue.5 , pp. 1011-1017
    • Sugiyama, T.1    Fujiwara, K.2    Ohashi, Y.3    Yokota, H.4    Hatae, M.5    Ohno, T.6    Nagai, Y.7    Mitsuhashi, N.8    Ochiai, K.9    Noda, K.10
  • 80
    • 0141998606 scopus 로고    scopus 로고
    • Molecular identification of a danger signal that alerts the immune system to dying cells
    • Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516-21.
    • (2003) Nature , vol.425 , Issue.6957 , pp. 516-521
    • Shi, Y.1    Evans, J.E.2    Rock, K.L.3
  • 88
    • 0025007730 scopus 로고
    • Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay
    • Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123(2):224-7.
    • (1990) Radiat Res , vol.123 , Issue.2 , pp. 224-227
    • Nakamura, N.1    Kusunoki, Y.2    Akiyama, M.3
  • 89
    • 84873129162 scopus 로고    scopus 로고
    • The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells
    • Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31(2):140-4.
    • (2013) Cancer Invest , vol.31 , Issue.2 , pp. 140-144
    • Yovino, S.1    Kleinberg, L.2    Grossman, S.A.3    Narayanan, M.4    Ford, E.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.